Home / Going-concern warnings / Verrica Pharmaceuticals Inc.
Filed 2026-05-12 路 Form 10-Q 路 Accession 0001660334-26-000014 micro
Price before filing: $7.4 (2026-05-11 close, split/dividend-adjusted)
Market cap at flag: $76.2M (2026-05-12) 路 Latest: $76.7M (2026-10-16)
| Window | VRCA | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -18.5% | -0.2% | -18.3% | 2026-06-11 |
| 90 days | -30.8% | +4.8% | -35.6% | 2026-08-10 |
| 180 days | pending | pending | until 2026-11-08 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"The Company plans to address the conditions that raise substantial doubt regarding its ability to continue as a going concern by, among other things, obtaining additional funding through equity offerings, debt financing, collaborations, strategic alliances and/or licensing arrangements."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2026-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.